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Abstract
In the last few years internet-based technologies played an important role 
in reinventing various medical procedures and facilitating quick access to medical 
services and care, particularly in the remote areas of China. The use of artificial 
intelligence and cloud computing in clinical laboratory setting for slide analysis 
contributed to standardized cytology and pathology diagnosis but more impor-
tantly slide analysis with artificial intelligence has a huge potential to compensate 
for a country wide lack of pathologists and systematic quality control. While 
well-established automated slide scanning is already in use, we added intelligent 
algorithms located in a secure cloud for the better slide readings, and mobile phone 
microscopes to capture those regions of Hubei province where laboratory infra-
structure is supported by high-speed internet and 5G networks. These technological 
advances allowed us to bring an important pathology expertise across the large 
areas of China.
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1. Introduction
The contemporary artificial intelligence techniques such as machine learning 
applications were widely used in medicine and achieved the substantial success, 
particularly in radiology, in the recent years [1, 2]. Most of the technologies to 
support AI in pathology are still in development phase or are at the state of an 
observational study [3]. They are not widely applied in a large-scale screening as 
a routine service. This chapter will explain why and how AI and cloud computing 
is deployed as a standard of care in Province of Hubei, China and will illustrate all 
advantages that artificial intelligence can add making cervical cancer screening 
efficient and economically sound. This model can be easily adapted anywhere in the 
world where cytology is the only method or is combined with HPV in the cervical 
cancer screening.
2. Cervical cancer in China
In December 2020 China’s National Health Commission (NHC) has voiced full 
support for the “Global Strategy to Accelerate the Elimination of Cervical Cancer” 
launched by the World Health Organization (WHO). According to data from 2018 
cervical cancer is the fourth most frequent malignant tumor in women [4]. The 
same report shows that there were approximately 570000 cases of cervical cancer 
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with estimated 310000 deaths globally. Peking University Health Care Center pub-
lished that after 2000, the incidence of cervical cancer in China is on the rise while 
the mortality rate stayed somewhat the same. In 2015 the number of newly diag-
nosed cervical cancer cases was 98900 and the number of deaths reached 30500. 
However, in 2018 the reported number of cases were 106000 with 48000 deaths, 
which shows that the cervical cancer is indeed on the rise. That is particularly true 
for the women in rural areas. Since 2009, Chinese health authorities initiated free 
large-scale population-based cervical cancer screening for rural women with low 
socioeconomic status totaling approximately 10 million people [5]. These early 
initiatives were important and laid the foundation for cervical cytology screening 
guideline development in China. It is fair to say that these early initiatives were also 
important for bringing awareness about the importance of cervical examination 
among women.
3. How cervical cancer screening methodology was introduced?
Detecting cervical precancerous lesions and implementing early screening fol-
lowed by early treatment intervention are proven essential steps in prevention and 
treatment of cervical cancer. Decrease in cervical cancer incidence in most western 
countries can be attributed to the success of screening using the Papanicolaou test 
(PAP-test) where this method has proved to effectively reduce cervical cancer 
incidence and mortality [6, 7]. PAP-test is based on detecting cellular changes that 
can progress into malignant changes but if detected at an early stage can be treated 
and prevent development of cervical cancer. It has been shown in many countries 
around the world that implementing PAP-test in systematic, comprehensive screen-
ing programs can reduce incidence of cervical cancer. In recent years, HPV-DNA 
virus examination methods have also been introduced into cervical cancer screen-
ing [8]. The success and program implementation differ among countries and so in 
China too, in certain areas it is introduced with questionable success. In the western 
countries for example in Canada and Japan, more traditional cytology analysis 
methods are still used [9], while UK, USA and Australia use HPV detection  
methods [10–12].
4. Why is AI and cloud computing the best approach for mass screening?
Due to China’s huge and growing population, a simple “mirror” of the European 
or American guidelines for cervical screening is not possible due to several major 
differences in the medical system organization: (1) In China, the primary point 
of sample collection is not a family physician office setting like in the most of the 
western countries, but gynecologist, or specially trained nurse (2) There is an insuf-
ficient number of laboratory professionals, particularly cytotechnicians to screen, 
read the slides and issue negative reports and (3) Organized quality control and 
assurance is not established nationwide and it varies from laboratory to laboratory. 
The lack of cytotechicians and cytopathologists in county’s and town’s level medi-
cal institutions make cervical cancer screening uneven thus in many places, the 
purpose of screening is lost [13].
In the recent years we saw rapid development in deep learning and artificial 
intelligence technologies. The intelligent recognition of medical images and 
counting method of deep learning has made possible the use of the artificial 
intelligence (AI) in diagnostic techniques such as X-ray, CT, mammography and 
pathology [14–17]. With the data quality and improvements of speed in automated 
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microscopes and whole slide scanners [18], telepathology was introduced as a first 
step for remote slide interpretation [19]. The adoption was slow however today 
telepathology is an integral part of almost every pathology laboratory particularly 
for second opinion. It was logical that the next technological development, the use 
of artificial intelligence in laboratory medicine came after years of research and 
systems training with millions of cervical specimens.
The first AI diagnostic techniques for use in a large-scale cervical cancer screen-
ing in primary hospitals without cytopathologists was implemented in Hubei 
province, China. It allowed diagnosis without physical transportation of samples 
(slides); data are analyzed in the cloud at the very high speed. When AI was intro-
duced (2017) it greatly reduced the financial, time cost and improved the accessibil-
ity of expert pathologist and fast turnaround for cytology results to patients [20]. 
These were the first steps towards today’s use of AI for slide scanning and robotic 
data analysis. Furthermore, today we do not even need the fully developed scanner, 
the new mobile phone microscopes particularly in the remote and rural areas are 
used and are already improving the way cervical cancer screening is delivered.
5.  The start of AI and cloud computing in cervical cancer screening, 
Hubei Province, China
In 2017, Hubei’s Provincial Health Authority authorized a cervical cancer screen-
ing program that used a unique cloud-based platform for cervical cancer screening, 
data gathering, analysis, review and reporting to provide screening services to rural 
women in the province. The project was authorized by Ethic Review Board who 
agreed to approve the project. Data were continuously collected and presented for a 
final authorization to use AI as a standard in a cervical cancer screening.
From January 1, 2018 to December 31, 2018, a total of 703,103 women were 
screened for cervical cancer and those data are published recently (Figure 1). The 
vast majority were women between 30 and 65 years of age. Out of the total number 
of women 30,035 (4.3%) were between the ages of 20 and 30, and 8,313 (1.2%) 
were over 65 years of age. All women were of low socioeconomic status and from 
83 counties in China’s Hubei Province. As mentioned earlier the objective of the 
program was to assess the feasibility of a cloud-based screening program and the 
management of healthcare statistics.
Without going into too many details, which are published elsewhere [21], our 
study showed high agreement rate for normal cytology grade between AI and 
manual reading. We showed that well-“trained AI system” can accurately classify 
normal cytology. In our case more than 99% of women classified as normal cytol-
ogy by AI were confirmed by manual reading, suggesting that most of women with 
normal cytology could be primarily excluded by AI. In other words, AI system 
identified majority of slides most likely to be normal as only needing rapid review. 
This was a very important finding for laboratories that handle over 1 million slides 
in a short period.
AI-assisted cytology showed increased sensitivity without substantial decrease 
in specificity for detection of CIN2+, compared with manual reading, in accordant 
with previous observational studies using automated cytology [18, 19]. In our study, 
the detection of histological CIN2+ among women classified as normal by manual 
reading and abnormal by AI, was substantially higher than that among women clas-
sified as normal by AI and abnormal by manual reading. The detection of CIN2+ 
in our study was higher than the national program (155 versus 125 per 100 000), 
which can perhaps be explained because all women were from rural areas whose 
incidence is higher than countries average.
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An important issue of cytology-based cervical cancer screening is the manage-
ment of women with ASC-US, in which detection of high-grade lesions or cancer 
varies greatly. Inappropriate triage may result in an over referral of colposcopy, or a 
delayed diagnosis and treatment. Although human papillomavirus test, genotyping 
or some biomarkers (e.g. methylation, p16/Ki-67) provide technology for triaging 
ASC-US, these algorithms are very limited in low-resource settings.
AI-assisted cytology system provides opportunities to address many difficul-
ties that cervical cancer screening in China is facing. In the mode of AI-assisted 
cytology-based cervical cancer screening, large number of slides are automatically 
scanned and transferred to electronic cytology images and classified by pre-trained 
deep learning algorithms. For example, our laboratory received over 2 million 
Figure 1. 
The main study flow and the points at which data were collected.
5
The Role of AI in Cervical Cancer Screening
DOI: http://dx.doi.org/10.5772/intechopen.98348
slides in 2019. Although the system is automated each abnormal (positive) slide is 
still reviewed by cytologists who can log in into the cloud and review remotely and 
randomly selected 10% negative for quality control purposes.
Although the performance of automated-assisted cytology reading as a primary 
screening was reported previously [22] to our best knowledge, our study was the 
largest scale population-based cervical cancer screening using AI-assisted cytology 
reading in the low- and middle-income countries followed by AI routine imple-
mentation for cervical cancer screening. Once data were presented to our health 
authorities, we were allowed to offer cervical cancer screening based on AI as a 
routine clinical service.
6. Current implementation
Landing complete AI system has three major key components: an automated 
slide scanner installed in laboratories of counites hospitals, data uploading, and 
cloud platform for data processing and storing. The cloud system also connects 
to end users (physicians and patients) providing them with test reports (patients 
receive only negative report directly on their cell phone). See Figure 2.
The system is continuously improved due to the increasing participation in 
large-scale cervical cancer screening activities and therefore database is growing 
exponentially. For example, parallel to our study in 2018, we performed addi-
tional analysis of more than 1.2 million cell samples, adding millions of micro-
scopic images to database. With increasing data, the algorithm is also upgraded 
and improved, leading to improved diagnosis and detection rates of cervical 
abnormalities.
In response to the need for timely reporting and analysis of massive data from 
dispersed areas, Landing has improved its data uploading and downloading effi-
ciencies. Data processing capacity of our “Cyto Cloud” is increased from processing 
30 million cell samples per day in the end of 2016 to 750 million per day by the end 
of 2018.
Figure 2. 
Operational steps within cervical cancer screening program.
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This mode is being proved to be practical in China and can be reproducible in 
other developing countries wherever cytology is used as only method or is com-
bined with HPV testing. Moreover, technological advancements and data accumula-
tion might enable the AI system to be more intelligent and used more generally in 
other diagnostic fields.
7. Conclusions
Further development of AI and cloud computing in laboratory medicine is 
inevitable. Once huge amount of data is collected and analyzed the basic unit of 
data collection is now ready for a new roll out. In collaboration with a mobile phone 
companies the next generation of automated scanners is in the form of handheld 
phone microscopes that can be used in a remote area without lot of infrastructure. 
(Landing Smart Hand held device) It is important to say that the mobile phone 
handheld microscope is not only limited for the use in the cervical cancer screening. 
It is and can be used for any cytology and/or histology slides. While cervical cancers 
samples are currently the only specimens that use AI for assisted analysis the hand-
held device can be used for assisted second opinion diagnosis of FNA or bronchial 
washings or any other type of cytology or histology slides.
AI, fast cloud computing through 5G networks is changing the way we deliver 
medicine today. These advances are offering tremendous opportunity for improve-
ment of screening programs, particularly in China where huge number of women 
need to be screened. At the same time our model can be easily applicable, adaptable 
and implemented anywhere in the world where there is a lack of laboratory profes-
sionals and there is a need for a cervical cancer screening improvement.
Conflict of interest
The authors declare no conflict of interest.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
7
The Role of AI in Cervical Cancer Screening
DOI: http://dx.doi.org/10.5772/intechopen.98348
References
[1] Hosny A, Parmar C, Quackenbush J, 
Schwartz LH, Aerts HJWL. Artificial 
intelligence in radiology. Nat Rev 
Cancer. 2018;18(8):500-510. 
doi:10.1038/s41568-018-0016-5
[2] Oren O, Gersh B, Bhatt D, Artificial 
intelligence in medical imaging; 
switching from radiographic 
pathological data to clinically 
meaningful endpoints The Lancet 
Digital Health 2020;vol 2(9):486-488. 
doi.org/10.1016/S2589-7500(20) 
30160-6
[3] Hu L, Bell D, Antani S, et al. An 
Observational Study of Deep Learning 
and Automated Evaluation of Cervical 
Images for Cancer Screening. J Natl 
Cancer Inst. 2019;111(9):923-932. 
doi:10.1093/jnci/djy225
[4] Arbyn M, Weiderpass E, Bruni L, 
Sanjosé S, Saraiya M, Ferlay J, Bray F ; 
Estimates of incidence and mortality of 
cervical cancer in 2018: a worldwide 
analysis The Lancet Global Health,2020; 
vol 8(2):191-203/doi.org/10.1016/
S2214-109X(19)30482-6
[5] Li J., Kang L., Qiao Y.: Review of the 
Cervical Cancer Disease Burden in 
Mainland China, Asian Pacific J Cancer 
Prev, 12, 1149-1153
[6] Cohen PA, Cervical Cancer, Lancet, 
2019, 393,169-182.
[7] Wang Y, Wei L, Liu J, Li S, Wang Q , 
Comparison of Cancer Incidence 
between China and the USA Cancer Biol 
Med 2012; 9: 128-132 doi: 10.3969/j
[8] Dickinson JA, Stankiewic A, 
Popadiuk C, et al. Reduced cervical 
cancer incidence and mortality in 
Canada: national data from 1932 to 
2006. BMC public health. 2012, 12:992
[9] Hamashima C., Aoki D., Miyagi E., 
et al., The Japanese Guideline for 
Cervical Cancer Screening, Jpn J Clin 
Oncol 2010 40(6)485-502
[10] NHS Cervical Screening Program 
2016 NHSCSP Publication number 20
[11] US Preventive Service Task Force: 
Screening for Cervical Cancer JAMA. 
2018;320(7):674-686
[12] Australian Institute of Health and 
Welfare: Cervical Cancer screening 2018
[13] Di J. Rutherford S., Chu C.: Review 
of the Cervical Cancer Burden and 
Population-Based Cervical Cancer 
Screening in China, Asian Pac J Cancer 
Prev., 2015 16 (17), 7401-740711.
[14] Wang L. Alexander C : Medical 
Application and Healthcare Based on 
Cloud Computing International Journal 
of Cloud Computing and Services 
Science (IJ-CLOSER) Vol.2, No.4, 
August 2014, pp. 217~225
[15] Lau J., Lehnert E., Sethi A., et al. 
The Cancer Genomics Cloud: 
Collaborative, Reproducible, and 
Democratized—A New Paradigm in 
Large-Scale Computational Research 
Cancer Res; 77(21) November 1, 2017
[16] Yang C., Huang Q ., Li Z., Liu K., 
Hu F. Big Data and cloud computing: 
innovation opportunities and 
challenges, International Journal of 
Digital Earth, 2017 10:1, 13-53
[17] Moreno P, Joly Y, Knoppers B 
Public-Private Partnership in Cloud–
Computing Services in the Context of 
Genomic Frontiers in Medicine 20 
January 2017
[18] Wu M, Yan C, Liu H, Liu Q , Yin Y. 
Automatic classification of cervical 
cancer from cytological images by using 
convolutional neural network. Biosci 
Rep. 2018 Nov 28;38(6):BSR20181769. 
doi: 10.1042/BSR20181769. Erratum in: 
Cervical Cancer - A Global Public Health Treatise
8
Biosci Rep. 2019 Apr 2;39(4): PMID: 
30341239; PMCID: PMC6259017.
[19] Evans AJ, Salama ME, 
Henricks WH, Pantanowitz L. 
Implementation of Whole Slide Imaging 
for Clinical Purposes: Issues to Consider 
From the Perspective of Early Adopters. 
Arch Pathol Lab Med. 2017 
Jul;141(7):944-959. doi: 10.5858/
arpa.2016-0074-OA. Epub 2017 Apr 25. 
PMID: 28440660.
[20] Dong Y, Bai J, Zhang Y , Shang G, 
Zhao Y , Li S , Yan N , Hao S, Zhang W, 
Automated Quantitative Cytology 
Imaging Analysis System in Cervical 
Cancer Screening in Shanxi Province, 
China Cancer and Clinical Oncology; 
2017, Vol. 6 (2); ISSN 1927-4858 E-ISSN 
1927-4866 doi:10.5539/cco.v6n2p51
[21] Bao H, Sun X, Zhang Y, Pang B, 
Li H, Zhou L, Wu F, Cao D, Wang J, 
Turic B, Wang L. The artificial 
intelligence-assisted cytology diagnostic 
system in large-scale cervical cancer 
screening: A population-based cohort 
study of 0.7 million women. Cancer 
Med. 2020 Sep;9(18):6896-6906. doi: 
10.1002/cam4.3296. Epub 2020 Jul 22. 
PMID: 32697872; PMCID: .
[22] Hu L, Bell D, Antani S, Xue Z, Yu K, 
Horning MP, Gachuhi N, Wilson B, 
Jaiswal MS, Befano B, Long LR, 
Herrero R, Einstein MH, Burk RD, 
Demarco M, Gage JC, Rodriguez AC, 
Wentzensen N, Schiffman M. An 
Observational Study of Deep Learning 
and Automated Evaluation of Cervical 
Images for Cancer Screening. J Natl 
Cancer Inst. 2019 Sep 1;111(9):923-932. 
doi: 10.1093/jnci/djy225. PMID: 
30629194; PMCID: PMC6748814.
